- 首页
- Glycogen synthase kinase 3 (GSK-3)
- BRD5648
BRD5648
BRD5648 ((R)-BRD0705) 是一种无活性的 BRD0705 的 R 型异构体，BRD0705 是一种有效的，具有旁系选择性和口服活性的 GSK3α 抑制剂，IC50 为 66 nM，Kd 为 4.8 μM。BRD0705 与 GSK3β (IC50 为 515 nM) 相比，对 GSK3α 的选择性更高 (8 倍)。BRD0705 可用于急性髓细胞性白血病。
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥5937.004750.00- +
-
10mg￥9600.007680.00- +
-
50mg￥26662.0021330.00- +
-
100mg￥44750.0035800.00- +
-
200mg￥0.000.00- +
-
500mg￥0.000.00- +
- 货号: ajcx16302
- CAS: 2056261-42-6
- 别名: (R)-BRD0705
- 分子式: C20H23N3O
- 分子量: 321.42
- 纯度: ＞98%
- 溶解度: DMSO: 300 mg/mL (933.36 mM)
- 储存: Store at -20°C
- 库存: 现货
Background
BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML)[1][2].
[1]. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. [2]. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460.
